Aim: Patent ductus arteriosus (PDA) is treated with ibuprofen and it is known that the clearance of ibuprofen increases with postnatal age. We aimed to study whether postnatal age-adjusted ibuprofen dosages improve the effectiveness of treatment compared to standard ibuprofen dosages after the first days of life. Methods: A historical cohort of 207 preterm neonates treated with standard ibuprofen dosages (Group A; 2011–2015) was compared to a prospective cohort of 66 preterm neonates treated with postnatal age-adjusted ibuprofen dosages (Group B; 2015–2016). Results: Both groups had comparable background characteristics. Treatment was started after median 6 (25–75th percentile: 4–11) and 5 (25–75th percentile: 4–11) days and effectiveness was 33.2 and 44.7% (p =.17) in groups A and B, respectively. No hemodynamically significant PDA was found in 23/49 (46.9%) of the patients born before 28 weeks after adjusted ibuprofen dosages compared to 48/162 (29.6%) after standard ibuprofen dosages (p =.04). There were significantly more reversible side effects with the postnatal age-adjusted ibuprofen dosages (p =.04). Conclusions: There seems to be a trend to higher effectiveness with the adjusted ibuprofen dosages in preterm neonates before 28 weeks, but it is associated with more reversible side effects.

Additional Metadata
Keywords development, dosing, ibuprofen, Patent ductus arteriosus, pharmacodynamics, preterm neonates
Persistent URL dx.doi.org/10.1080/14767058.2019.1667323, hdl.handle.net/1765/120618
Journal The Journal of Maternal - Fetal & Neonatal Medicine
Citation
de Klerk, J.C.A, van Paassen, N. (Nanda), van Beynum, I.M, Flint, R.B, Reiss, I.K.M, & Simons, S.H. (2019). Ibuprofen treatment after the first days of life in preterm neonates with patent ductus arteriosus. The Journal of Maternal - Fetal & Neonatal Medicine. doi:10.1080/14767058.2019.1667323